Badger Meter Inc vs Heron Therapeutics Inc — how do they compare? Badger Meter Inc trades at $135.56 (market cap $3.95B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Badger Meter Inc is far larger — about 62.3× Heron Therapeutics Inc's market cap, and Badger Meter Inc pays a 1.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BMI | HRTX | |
|---|---|---|
Market Cap | $3.95B | $63.41M |
Sector | Technology | Health |
52-Week High | $193.09 | $1.49 |
52-Week Low | $113.41 | $0.32 |
Enterprise Value | $3.86B | $161.31M |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.
The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →